Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: Further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity

Journal of Medicinal Chemistry

Volumn 42, Issue 21, 1999, Pages 4462-4470

  Campiani, Giuseppe ^a   Morelli, Elena ^b   Fabbrini, Monica ^b   Nacci, Vito ^b   Greco, Giovanni ^c   Novellino, Ettore ^c   Ramunno, Anna ^c   Maga, Giovanni ^e   Spadari, Silvio ^e   Caliendo, Giuseppe ^c   Bergamini, Alberto ^d   Faggioli, Emanuela ^d   Uccella, Ilaria ^d   Bolacchi, Francesca ^d   Marini, Stefano ^d   Coletta, Massimiliano ^d   Nacca, Angelo ^f   Caccia, Silvio ^f  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e Ist Genet Biochim ed E   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; OXAZEPINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-HIV AGENTS; AZEPINES; CELL LINE; DRUG DESIGN; DRUG SYNERGISM; FLUORESCENT ANTIBODY TECHNIQUE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICE; MODELS, MOLECULAR; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; ZIDOVUDINE;

EID: 0032747299     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990150o     Document Type: Article

References (51)

1. De Clercq, E. HIV Inhibitors Targeted at the Reverse Transcriptase. AIDS Res. Hum. Retrovirus 1992, 8, 119-134.
2. Therapeutic Approaches to HIV. Perspect. Drug Discovery Des. 1993 1, 1-250.
3. (a) Powell, K. L.; Darby, G. HIV Reverse Transcriptase as a Target for Antiviral Drugs. In Design of Anti-AIDS Drugs; DeClercq, E., Ed.; Elsevier: New York, 1990; pp 123-140.
4. (b) Goff, S. P. Retroviral reverse Transcriptase: Synthesis, Structure, and Function. J. AIDS 1990, 3, 817-831.
5. Mitsuya, H.; Broder, S. Strategies for Antiviral Therapy in AIDS. Nature 1987, 325, 773-778.
6. Young, S. D. Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. Perspect. Drug Discovery Des. 1993, 1, 181-192.
7. Terasaki, T.; Pardridge, W. M. Restricted Transport of 3′-Azido-3′-deoxythymidine and Dideoxynucleosides Through the Blood-Brain Barrier. J. Infect. Dis. 1988, 158, 630-632.
8. Kumar, R.; Wang, L.; Wiebe, L. I.; Knaus, E. E. Synthesis and Antiviral (HIV-1, HBV) Activities of 5-Halo-6-methoxy(or azido)-5,6-dihydro-3′-fluoro-3′-deoxythymidine Diastereomers. Potential Prodrugs to 3′-Fluoro-3′-deoxythymidine. J. Med. Chem. 1994, 37, 3554-3560.
9. Richman, D. D. Resistance of Clinical Isolates of Human Immunodeficiency Virus to Antiretroviral Agents. Antimicrob. Agents Chemother. 1993, 37, 1207-1221.
10. (a) Hargrave, K. D.; Proudfoot, J. R.; Grozinger, K. G.; Cullen, E.; Kapadia, S. R.; Patel, U. R.; Fuchs, V. U.; Mauldin, S. C.; Vitous, J.; Behnke, M. L.; Klunder, J. M.; Pal, K.; Skiles, J. W.; McNeil, D. W.; Rose, J. M.; Chow, G. C.; Skoog, M. T.; Wu, J. C.; Schmidt, G.; Engel, W. W.; Eberlein, W. G.; Saboe, T. D.; Campbell, S. J.; Rosenthal, A. S.; Adams, J. Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones. J. Med. Chem. 1991, 34, 2231-2241 and references therein,
11. (b) Cohen, K. A.; Hopkins, J.; Ingraham, R. H.; Pargellis, G.; Wu, J. C.; Palladino, D. E. H.; Kinkade, P.; Warren, T. C.; Rogers, S.; Adams, J.; Farina, P. R.; Grob, P. M. Characterization of the Binding Site of Nevirapine (BI-RG-587), a Non-Nucleoside Inhibitor of Human Immunodeficiency Virus Type-1 Reverse Transcriptase. J. Biol. Chem. 1991, 266, 14670-14674.
12. Klunder, J. M.; Hargrave, K. D.; West, M.; Cullen, E.; Pal, K.; Behnke, M. L.; Kapadia, S. R.; McNeil, D. W.; Wu, J. C.; Chow, G. C.; Adams, J. Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2. Tricyclic Pyridobenzoxazepinones and Dibenzoxazepmones. J. Med. Chem. 1992, 35, 1887-1897.
13. (a) Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M. J.; Breslin, H. J.; Raeymaeckers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J.; Schellekens, K.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and Selective Inhibition of HIV-1 Replication In Vitro by a Novel Series of TIBO Derivatives. Nature 1990, 343, 470-474.
14. (b) Breslin, H. J.; Kukla, M. J.; Ludovici, D. W.; Mohrbacher, R.; Ho, W.; Miranda, M.; Rodgers, J. D.; Hitchens, T. K.; Leo, G.; Gauthier, D. A.; Ho, C. Y.; Scott, M. K.; De Clercq, E.; Pauwels, R.; Andries, K.; Janssen, M. A. C.; Janssen, P. A. J. Synthesis and Anti-HIV-1 Activity of 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one (TIBO) Derivatives. J. Med. Chem. 1995, 38, 771-793.
15. Cantrell, A. S.; Engelhardt, P.; Hogberg, M.; Jaskunas, S. R.; Johansson, N. G.; Jordan, C. L.; Kangasmetsa, J.; Kinnick, M. D.; Lind, P.; Morin, J. M. Jr.; Muesing, M. A.; Noreen, R.; Oberg, B.; Pranc, P.; Sahlberg, C.; Ternansky, R. J.; Vasileff, R. T.; Vrang, L.; West, S. J.; Zhang, H. Phenethylthiazolylthiourea (PETT) Compounds as a New Class of HW-1 Reverse Transcriptase Inhibitors. 2. Synthesis and Further Structure -Activity Relationship Studies of PETT Analogues. J. Med. Chem. 1996, 39, 4261-4274.
16. Goldman, M. E.; Nunberg, J. H.; O'Brien, J. A.; Quintero, J. C.; Schleif, W. A.; Freund, K. F.; Gaul, S. L.; Saari, W. S.; Wai, J. S.; Hoffman, J. M.; Anderson, P. S.; Hupe, D. J.; Emini, E. A.; Stern, A. M. Pyridone Derivatives: Specific Human Immuno-deficiency Virus Type-1 Reverse Transcriptase Inhibitors with Antiviral Activity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6863-6867.
17. (a) Sardana, V. V.; Emini, E. A.; Gotlib, L.; Graham, D. J.; Lineberger, J. A.; Long, W. J.; Schlabach A. J.; Wolfang, J. A.; Condra, J. H. Functional Analysis of HIV-1 Reverse Transcriptase Amino Acids Involved in Resistance to Multiple Non-Nucleoside Inhibitors. J. Biol. Chem. 1992, 267, 17526-17530.
18. (b) Nunberg, J. H.; William, A. S.; Boots, E. J.; O'Brien, J. A.; Quintero, J. C.; Hoffman, J. M.; Emini, E. A.; Goldman, M. E. Viral Resistance to Human Immunodeficiency Virus Type 1-Specific Pyridinone Reverse Transcriptase Inhibitors. J. Virol. 1991, 65, 4887-4892.
19. De Clercq, E. Resistance to Reverse Transcriptase Inhibitors. Biochem. Pharmacol. 1994, 47, 155-169.
20. Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R. G.; Boyer, P. L.; Hughes, S. H.; Pauwels, R.; Andries, K.; Janssen, P. A. J.; Arnold, E. Locations of Anti-AIDS Drug Binding Sites and Resistance Mutations in the Three-Dimensional Structure of HIV-1 Reverse Transcriptase. J. Mol. Biol. 1994, 243, 369-387.
21. Campiani, G.; Nacci, V.; Fiorini, I.; De Filippis, M. P.; Garofalo, A.; Greco, G.; Novellino, E.; Altamura, S.; Di Renzo, L. Pyrrolobenzothiazepinones and Pyrrolobenzoxazepinones: Novel and Specific Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors with Antiviral Activity. J. Med. Chem. 1996, 39, 2672-2680.
22. Artico, M.; Porretta, G. C.; De Martino, G. Synthesis of 4H-Pyrrolo[2,1-c][1,4]benzoxazine. J. Heterocycl. Chem. 1971, 8, 283-287.
23. (a) Fiorini, I.; Nacci, V.; Ciani, S. M.; Garofalo, A.; Campiani, G.; Savini, L.; Novellino, E.; Greco, G.; Bernasconi, P.; Mennini, T. Novel Ligands Specific for Mithocondrial Benzodiazepine Receptors: 6-Arylpyrrolo[2,1-d][1,5]benzothiazepine Derivatives. Synthesis, Structure - Activity Relationships, and Molecular Modeling Studies. J. Med. Chem. 1994, 37, 1427-1438 and references therein,
24. (b) Campiani, G.; Nacci, V.; Fiorini, I.; De Filippis, M. P.; Garofalo, A.; Ciani, S. M.; Greco, G.; Novellino, E.; Williams, C. D.; Zisterer, D. M.; Woods, M. J.; Mihai, C.; Manzoni, C.; Mennini, T. Synthesis, Biological Activity, and SARs of Pyrrolobenzoxazepine Derivatives, a New Class of Specific "Peripheral-Type" Benzodiazepine Receptor Ligands. J. Med. Chem. 1996, 39, 3435-3450.
25. De Luca, C.; Inesi, A.; Rampazzo, L. J. Chem. Soc. Perkin Trans. 2 1985, 209-212.
26. Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; Stammers, D. High-Resolution Structures of HIV-RT from four RT-Inhibitor Complexes. Nature Struct. Biol. 1994, 2, 293-302.
27. Ren, J.; Eusnof, R.; Hopkins, A.; Ross, C.; Jones, Y.; Stammers, D. K.; Stuart, D. I. The Structure of HIV-1 Reverse Transcriptase Complexed with 9-Chloro-TIBO: Lessons for Inhibitor Design. Structure 1995, 3, 915-926.
28. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K.; Stuart, D. I. Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
29. Semiempirical quantum-mechanics calculations on benzene and thiophene, using the AM1 and PM3 Hamiltonians available in the MOPAC program (version 6.0, QCPE), indicate that the energy associated with the lowest unoccupied molecular orbital (LUMO) of the latter ring is 0.3 or 0.6 eV, respectively, lower. These data support that the 2-thienyl has a higher propensity with respect to the phenyl substituent to act as electron-acceptor in π-stacking charge-transfer interactions with electron-donor aromatic rings.
30. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 RT/TIBO R 86183 Complex Reveals Similarity in the Binding of Diverse Non-Nucleoside Inhibitors. Nature Struct. Biol. 1995, 2, 407-415.
31. Mager, P. P. Evidence of a Butterfly-Like Configuration of Structurally Diverse Allosteric Inhibitors of the HIV-I Reverse Transcriptase. Drug Des. Discovery 1996, 14, 241-257.
32. This apparent discrepancy could be due to genetic variability that exists among HIV-1 wild types and laboratory strains such as HIV-1wt and HIV-1III Ba-L. This variability can possibly account for the different antiviral activity shown by the tested compounds with respect to the viral strain used in the assays.
33. De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517.
34. High subcutaneous doses of these compounds may be irregularly absorbed in mice, but because of methodological limitations these doses were necessary for quantification in mouse tissue. This enabled us to establish that compounds of this type achieve higher concentrations in the mouse brain than in plasma, although plasma levels were generally below the limit of quantification, precluding any estimate of the brain-to-plasma ratios.
35. Brain concentrations of 13i were not corrected for the compound contributed by residual blood because in terms of concentrations this amounted to less than 1% of the brain concentrations.
36. SYBYL Molecular Modeling System (version 6.2); Tripos Inc., St. Louis, MO.
37. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, T. The Protein Data Bank: A Computer Based Archival File for Macromolecular Structures. J. Mol. Biol. 1977, 112, 535-542.
38. Dewar, M. J.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
39. Stewart, J. J. P. Optimization of Parameters for Semiempirical Methods. 1. The PM3 Methodol. J. Comput. Chem. 1989, 10, 209-220.
40. Maga, G.; Amacker, M.; Ruel, N.; Hubsher, U.; Spadari, S. Resistance to Nevirapine of HIV-1 Reverse Transcriptase Mutants: Loss of Stabilizing Interactions and Thermodynamic or Steric Barriers are Induced by Different Single Amino Acid Substitutions. J. Mol. Biol. 1997, 274, 738-747.
41. Weislow, O. W.; Kiser, R.; Fine, B.; Bader, J.; Shoemaker, R.; Boyd, M. R. New Soluble-formazan Assay for HIV-1 Cytopathic Effects: Application of High-flux Screening of Synthetic and Natural Products for AIDS-antiviral Activity. J. Natl. Cancer Inst. 1989, 81, 577-586.
42. Perno, C. F.; Yarchoan, R.; Cooney, D. A. Inhibition of Human Immunodeficiency Virus (HIV-1/HTLV-II-Ba-1) Replication in Fresh and Cultured Human Peripheral Blood Monocytes/Macrophages by Azidothymidine and Related 2′,3′-Dideoxynucleosides. J. Exp. Med. 1988, 168, 1111-1125.
43. Sodroski, J. G.; Rosen, C. A.; Haseltine, W. A. Trans-acting Transcriptional Activation of the Long Terminal Repeat of Human T Lymphotropic Viruses in Infected Cells. Science 1984, 225, 381-385.
44. Popovic, M.; Sarngadharen, M. G.; Read, E.; Gallo, R. C. Detection, Isolation and Continuos Production of Cytopathic Retrovirus (HTLV-III) from Patients with AIDS and pre-AIDS. Science 1984, 224, 497-500.
45. Gartner, S.; Markovits, P.; Markovitz, D. M.; Kaplan, M. H.; Gallo, R. C.; Popovic, M. The Role of Mononuclear Phagocytes in HTLV-III/LAV Infection. Science 1986, 233, 1533-1544.
46. Karber, G. Beitrag zur Kollektiven Behandlung Pharmakologischer Reihenversuche. Arch. Exp. Pharmakol. 1931, 762, 480-483.
47. Bergamini, A.; Perno, C. F.; Capozzi, M. A Tetrazolium-Based Colorimetric Assay for Quantification of HFV-1-Induced Cytopathogenicity in Monocyte-Macrophages Exposed to Macrophage-Colony Stimulating Factor. J. Virol. Methods 1992, 40, 275-286.
48. Pauwels, R.; Balzarini, J.; Baba, M. Rapid and Automated Tetrazolium Based Colorimetric Assay for the Detection of Anti-HIV Compounds. J. Virol. Methods 1988, 20, 309-321.
49. Chou, T. C. Derivation and Properties of Micaelis-Menten Type and Hill Type Equations for Reference Ligands. J. Theoret. Biol. 1976, 59, 253-276.
50. D'Atri, S.; Tentori, L.; Fuggetta, M. P.; Marini, S.; Bonmassar, E. A Miniaturized Cell-mediated Cytotoxicity Assay with Human Effector Mononuclear Cells. Int. J. Tissue React. 1986, VII (5), 383-390.
51. Chou, T. C.; Talalay, I. Quantitative Analysis of Dose-Effect Relationships: the Combined Effects of Multiple Drugs or Enzyme Inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.